• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DECITABINE Drug Record

  • Summary
  • Interactions
  • Claims
  • DECITABINE chembl:CHEMBL1201129 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    NSC-127716
    DACOGEN
    DECITABINE
    DAC
    DACOGEN®
    AZADC
    5-AZADEOXYCYTIDINE
    4-AMINO-1-(2-DEOXY-BETA-D-ERYTHRO-PENTOFURANOSYL)-S-TRIAZIN-2(1H)-ONE
    rxcui:15657
    chemidplus:2353-33-5
    drugbank:01262
    pubchem.compound:451668
    chembl:CHEMBL1201129

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 2006
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (7 More Sources)

    Publications:

    Lou et al., 2014, Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells., PLoS ONE
    Turcan et al., 2013, Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine., Oncotarget
    Saba et al., 2005, Decitabine in myelodysplastic syndromes., Semin. Hematol.
    Daskalakis et al., 2010, Decitabine., Recent Results Cancer Res.
    Ando et al., 2000, Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells., Leukemia
    Saunthararajah et al., 2003, Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease., Blood
    Jabbour et al., 2008, Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies., Cancer
    Karpf et al., 2001, Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine., Mol. Pharmacol.
    Stresemann et al., 2008, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine., Int. J. Cancer
    Csankovszki et al., 2001, Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation., J. Cell Biol.
    Oki et al., 2007, Decitabine--bedside to bench., Crit. Rev. Oncol. Hematol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Takebayashi et al., 2001, 5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation., Biochem. Biophys. Res. Commun.
    Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.
    Bakker et al., 2002, Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells., J. Biol. Chem.
    Zhong et al., 2002, Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas., Clin. Cancer Res.
    Coombs et al., 2016, Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia., Haematologica
    Metzeler et al., 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia., Leukemia
    Bejar et al., 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients., Blood
    Gratchev et al., 2001, Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation., Cancer Lett.
    Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.
  • DECITABINE   DNMT3A

    Interaction Score: 7.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type predicted – sensitive
    Approval Status Clinical Study

    PMIDs:
    27418649 22124213


    Sources:
    JAX-CKB ChemblInteractions CIViC

  • DECITABINE   ASXL1

    Interaction Score: 5.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    25224413


    Sources:
    JAX-CKB

  • DECITABINE   MUC2

    Interaction Score: 3.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11368880


    Sources:
    NCI

  • DECITABINE   TET2

    Interaction Score: 3.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    25224413


    Sources:
    JAX-CKB

  • DECITABINE   DNMT1

    Interaction Score: 3.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor
    Direct Interaction yes
    Trial Name Dacogen/decitabine

    PMIDs:
    16015501 20072836 11069027 12907443 18398832 11259619 18425818 11352938 17023173 11752352 11688997 25968887


    Sources:
    TdgClinicalTrial ChemblInteractions TEND CIViC

  • DECITABINE   IL2RA

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15814281


    Sources:
    NCI

  • DECITABINE   GSTP1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11960994 11948118


    Sources:
    NCI

  • DECITABINE   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25968887


    Sources:
    CIViC

  • DECITABINE   EGFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    24874286


    Sources:
    JAX-CKB

  • DECITABINE   IDH1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type oligodendroglioma
    Response Type sensitive
    Approval Status Preclinical - Pdx & cell culture

    PMIDs:
    24077826


    Sources:
    JAX-CKB

  • DECITABINE   GMNN

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: DECITABINE

    • Version: 01-August-2011

    Alternate Names:
    DECITABINE Primary Drug Name

    Drug Info:
    Year of Approval 2006
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: DECITABINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: DAC

    • Version: 14-September-2017

    Alternate Names:
    C981 NCI drug code

    Drug Info:

    Publications:
    Forrest et al., 2005, Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?, Transpl. Immunol.

  • NCI: 5-AZADEOXYCYTIDINE

    • Version: 14-September-2017

    Alternate Names:
    C981 NCI drug code

    Drug Info:

    Publications:
    Zhong et al., 2002, Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas., Clin. Cancer Res.
    Bakker et al., 2002, Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells., J. Biol. Chem.
    Gratchev et al., 2001, Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation., Cancer Lett.

  • JAX-CKB: Decitabine

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bejar et al., 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients., Blood
    Lou et al., 2014, Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells., PLoS ONE
    Coombs et al., 2016, Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia., Haematologica

  • CIViC: DECITABINE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Metzeler et al., 2012, DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia., Leukemia
    Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.

  • TTD: Decitabine

    • Version: 2020.06.01

    Alternate Names:
    D0X5XU TTD Drug ID

    Drug Info:

    Publications:

  • DTC: DECITABINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1201129 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201129

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: DECITABINE

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201129

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21